IBDEI0H6 ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,7680,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7680,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7680,1,4,0)
 ;;=4^N01.4
 ;;^UTILITY(U,$J,358.3,7680,2)
 ;;=^5015505
 ;;^UTILITY(U,$J,358.3,7681,0)
 ;;=N01.5^^52^518^68
 ;;^UTILITY(U,$J,358.3,7681,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7681,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,7681,1,4,0)
 ;;=4^N01.5
 ;;^UTILITY(U,$J,358.3,7681,2)
 ;;=^5015506
 ;;^UTILITY(U,$J,358.3,7682,0)
 ;;=N01.6^^52^518^63
 ;;^UTILITY(U,$J,358.3,7682,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7682,1,3,0)
 ;;=3^Rapidly progr neph synd w/ dense deposit disease
 ;;^UTILITY(U,$J,358.3,7682,1,4,0)
 ;;=4^N01.6
 ;;^UTILITY(U,$J,358.3,7682,2)
 ;;=^5015507
 ;;^UTILITY(U,$J,358.3,7683,0)
 ;;=N01.7^^52^518^66
 ;;^UTILITY(U,$J,358.3,7683,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7683,1,3,0)
 ;;=3^Rapidly progr neph synd w/ diffuse crescentic glomrlneph
 ;;^UTILITY(U,$J,358.3,7683,1,4,0)
 ;;=4^N01.7
 ;;^UTILITY(U,$J,358.3,7683,2)
 ;;=^5015508
 ;;^UTILITY(U,$J,358.3,7684,0)
 ;;=N01.8^^52^518^71
 ;;^UTILITY(U,$J,358.3,7684,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7684,1,3,0)
 ;;=3^Rapidly progr neph synd w/ oth morphologic changes
 ;;^UTILITY(U,$J,358.3,7684,1,4,0)
 ;;=4^N01.8
 ;;^UTILITY(U,$J,358.3,7684,2)
 ;;=^5015509
 ;;^UTILITY(U,$J,358.3,7685,0)
 ;;=N01.9^^52^518^72
 ;;^UTILITY(U,$J,358.3,7685,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7685,1,3,0)
 ;;=3^Rapidly progr neph synd w/ unsp morphologic changes
 ;;^UTILITY(U,$J,358.3,7685,1,4,0)
 ;;=4^N01.9
 ;;^UTILITY(U,$J,358.3,7685,2)
 ;;=^5015510
 ;;^UTILITY(U,$J,358.3,7686,0)
 ;;=N02.0^^52^518^80
 ;;^UTILITY(U,$J,358.3,7686,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7686,1,3,0)
 ;;=3^Recurrent & perst hematur w/ minor glomerular abnlt
 ;;^UTILITY(U,$J,358.3,7686,1,4,0)
 ;;=4^N02.0
 ;;^UTILITY(U,$J,358.3,7686,2)
 ;;=^5015511
 ;;^UTILITY(U,$J,358.3,7687,0)
 ;;=N02.1^^52^518^79
 ;;^UTILITY(U,$J,358.3,7687,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7687,1,3,0)
 ;;=3^Recurrent & perst hematur w/ focal & seg glomerular lesions
 ;;^UTILITY(U,$J,358.3,7687,1,4,0)
 ;;=4^N02.1
 ;;^UTILITY(U,$J,358.3,7687,2)
 ;;=^5015512
 ;;^UTILITY(U,$J,358.3,7688,0)
 ;;=N02.2^^52^518^77
 ;;^UTILITY(U,$J,358.3,7688,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7688,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse membranous glomrlneph
 ;;^UTILITY(U,$J,358.3,7688,1,4,0)
 ;;=4^N02.2
 ;;^UTILITY(U,$J,358.3,7688,2)
 ;;=^5015513
 ;;^UTILITY(U,$J,358.3,7689,0)
 ;;=N02.3^^52^518^74
 ;;^UTILITY(U,$J,358.3,7689,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7689,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus mesangial prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7689,1,4,0)
 ;;=4^N02.3
 ;;^UTILITY(U,$J,358.3,7689,2)
 ;;=^5015514
 ;;^UTILITY(U,$J,358.3,7690,0)
 ;;=N02.4^^52^518^73
 ;;^UTILITY(U,$J,358.3,7690,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7690,1,3,0)
 ;;=3^Recur & perst hematur w/ diffus endocaplry prolif glomrlneph
 ;;^UTILITY(U,$J,358.3,7690,1,4,0)
 ;;=4^N02.4
 ;;^UTILITY(U,$J,358.3,7690,2)
 ;;=^5015515
 ;;^UTILITY(U,$J,358.3,7691,0)
 ;;=N02.5^^52^518^78
 ;;^UTILITY(U,$J,358.3,7691,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7691,1,3,0)
 ;;=3^Recurrent & perst hematur w/ diffuse mesangiocap glomrlneph
 ;;^UTILITY(U,$J,358.3,7691,1,4,0)
 ;;=4^N02.5
 ;;^UTILITY(U,$J,358.3,7691,2)
 ;;=^5015516
 ;;^UTILITY(U,$J,358.3,7692,0)
 ;;=N02.6^^52^518^75
 ;;^UTILITY(U,$J,358.3,7692,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,7692,1,3,0)
 ;;=3^Recurrent & perst hematur w/ dense deposit disease
